ramucirumab + atezolizumab + N-803

This drug is a combination of three agents: **ramucirumab** (a monoclonal antibody targeting VEGFR2, inhibiting angiogenesis), **atezolizumab** (a monoclonal antibody targeting PD-L1, acting as an immune checkpoint inhibitor), and **N-803** (also known as ALT-803, an interleukin-15 [IL-15] superagonist immunostimulatory protein that enhances natural killer and CD8+ T cell proliferation and activation). The combination is being investigated primarily for treatment of **advanced or metastatic non-small cell lung cancer (NSCLC)** in patients who have progressed after previous therapy with immune checkpoint inhibitors. Ramucirumab is developed by Eli Lilly and blocks angiogenesis, atezolizumab is developed by Roche/Genentech and blocks tumor immune evasion, and N-803 (developed by ImmunityBio) is a novel IL-15 receptor superagonist designed to potentiate anti-tumor immune responses[1][3][5][8].

Other names

ramucirumabatezolizumab